Clinical utility of novel biosensing platform: Diagnosis of coronavirus SARS-CoV-2 at point of care

Alaa A.a. Aljabali, Kaushik Pal, Angel Serrano-aroca, Kazuo Takayama, Kamal Dua, Murtaza M. Tambuwala

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
4 Downloads (Pure)


Early detection is the first step in the fight against severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2). Therefore, an efficient, rapid, selective, specific, and inexpensive SARS-CoV-2 diagnostic method is the need of the hour. The reverse transcription-polymerasechain reaction (RT-PCR) technology is massively utilized to detect infection with SARS-CoV-2. However, scientists continue to strive to create enhanced technology while continually developing nanomaterial-enabled biosensing methods that can provide new methodologies, poten-tially fulfilling the present demand for rapid and early identification of coronavirus disease 2019 (COVID-19) patients. Our review presents a summary of the recent diagnosis of SARS-CoV-2 of COVID-19 pandemic and nanomaterial-available biosensing methods. Although limited research on nanomaterials-based nanosensors has been published, allowing for biosensing approaches for diagnosing SARS-CoV-2, this study highlights nano-materials that provide an enhanced biosensing strategy and potential processes that lead to COVID-19 diagnosis
Original languageEnglish
Number of pages4
JournalMaterials Letters
Early online date6 Aug 2021
Publication statusPublished (in print/issue) - 1 Dec 2021

Bibliographical note

© 2021 Elsevier B.V. All rights reserved.


  • SARS-CoV-2
  • Nanomaterials
  • Biosensors
  • Polymerase chain reaction
  • COVID-19 clinical diagnostics


Dive into the research topics of 'Clinical utility of novel biosensing platform: Diagnosis of coronavirus SARS-CoV-2 at point of care'. Together they form a unique fingerprint.

Cite this